Jerome Hamilton, CEO of Open Therapeutics, leads the company's scale and global expansion, as well as manages business development, sales, marketing, and investor relations. He joined Open TherapeuticsTM after serving as Stratasys’ Senior Vice President of Global Operations, before which he was Vice President of LEAN Six Sigma Operations, Corporate Quality and Acquisition Integration for 3M. There, he played a major role in devising strategy and operational plans for the company’s largest business group, Industrial Business Group. He also led the company’s Masking and Surface Protection Business with full P&L responsibility.
Hamilton received his Bachelor of General Science from Morehouse College, his Bachelor of Science in Industrial Engineering from Georgia Tech, Master of Science in Engineering Management from University of Detroit, Mercy; and Master of Science for International Logistics from Georgia Tech; he is a graduate of the Advanced Management Program, Harvard Business School.
Hamilton is a member of the Boards of Directors of Goodwill Easter Seals Minnesota, Real Life 101, and V2SOFT. He was listed in the 2014 Savoy Magazine list of Most Influential Blacks in Corporate America and was recognized as one of the Top 50 diversity professionals in industry– Global Diversity List, supported by The Economist, (
globaldiversitylist.com).
In the coming months Open TherapeuticsTM will provide to global researchers, a crowdsourcing web platform that will host freely available open pharma and medical technologies framework, created by Jason Barkeloo and his team, to global researchers. Scientists can freely adopt the open technologies and develop manuscripts on the science they conduct around the technologies.
About Open TherapeuticsTM LLC
Open TherapeuticsTM is a seven-year old company that curates and develops open medical, biopharma, and synthetic biology-based biotechnologies. Among the technologies being freely opened and crowdsourced to the global community are essential proteins for developing antibiotic and anticancer therapeutics, immunotherapy and oncolytics, and biomarker inducers. The Company is headquartered in Cincinnati, Ohio with laboratory operations in Covington, Kentucky, USA, and Madrid, Spain via its strategic partner, Bacmine SL, (
www.bacmine.com ).
